Analyst Rating Update: Rockwell Medical, Inc. (NASDAQ:RMTI) - Markets Daily Print

Wall Street analysts have placed a target price of $16.6 for Rockwell Medical, Inc. (NASDAQ:RMTI). This number is based on the mean consensus estimate from the 5 research firms that recently issued reports on the stock.

The average broker recommendation is arithmetical average of the individual ratings contributed by sell-side analysts to produce a Consensus Analyst Rating for each stock. On a scale of 1 to 5 where 1 is a Strong Buy and 5 is a Strong Sell, has the stock ranked 2.2 based on 5 broker recommendations. Of the 5 analysts who have issued estimates, the most bullish sees the stock reaching $26 within the next 12 months while the most conservative sees the stock at $4 within the year. According to analysts, Rockwell Medical, Inc. (NASDAQ:RMTI) is expected to report earnings per share for the current fiscal quarter of $-0.02. This is the consensus mean estimate based on the individual covering sell-side analysts’ reported numbers. The company last reported earnings for the period ending on 2015-06-30 of $-0.05. The reported number was 0.05 away from the consensus estimate, or a surprise factor of 50 . In looking at the long term growth prospects of the company, sell-side analysts have a consensus mean earnings per share estimate for the current year of $0.09. The high end estimate for this time frame is $0.22 with the low being $-0.08. Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patient’s bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol.